eligibility_summary
Eligibility: adults (≥18) treated with alemtuzumab for severe or glucocorticoid-resistant kidney transplant rejection. Exclusions: prior use of other lymphocyte-depleting therapy (e.g., rATG) for the same episode, pre-therapy T-cell count <200×10^6/L, inability to provide written consent.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Prospective observational cohort of adults given reduced-dose alemtuzumab for severe or steroid-resistant kidney transplant rejection. Drug: Alemtuzumab, a humanized anti-CD52 monoclonal antibody (lymphocyte-depleting immunosuppressant). Mechanism: binds CD52 on mature lymphocytes, inducing profound T- and B-cell depletion via ADCC, complement-mediated cytotoxicity, and apoptosis, can also reduce some NK cells/monocytes. Targets/pathways: CD52+ T and B cells driving cellular/humoral alloimmunity. The study profiles lymphocyte repopulation, TCR/BCR intracellular signaling, cytokines, donor-specific T-cell responses, and biomarkers (donor-derived cfDNA, nucleosomes, urinary chemokines, extracellular vesicles).